Categories
Change Password!
Reset Password!
Ozoralizumab rapidly improves disease activity and physical function and limits joint damage in rheumatoid arthritis patients regardless of large joint involvement.
A new analysis of the OHZORA and NATSUZORA trials yields strong evidence that ozoralizumab delivers consistent clinical benefits in patients with rheumatoid arthritis (RA), irrespective of the presence of large joint involvement (LJI)—a condition often connected with higher disease burden and disability.
This post-hoc analysis examined Japanese RA patients treated with 30 mg ozoralizumab every 4 weeks for 52 weeks across two randomized trials:
Volunteers were categorized based on LJI, defined as swelling in shoulder, elbow, knee, or ankle joints. Outcomes assessed incorportaed disease activity, physical function, inflammatory biomarkers, and joint damage progression. Completion rates were similar across all subgroups, depicting consistent treatment adherence.
Those with LJI had markedly greater Clinical Disease Activity Index (CDAI) scores, reflecting more severe ailment at baseline. However, this difference disappeared rapidly—by day 3 of treatment—and remained comparable thereafter. Both patient groups experienced:
In those with LJI, key inflammatory biomarkers illustrated continuous improvement:
Radiographic assessment revealed that changes in modified total sharp score at week 24 were same between groups in the OHZORA trial, suggesting comparable inhibition of joint damage progression. Overall, ozoralizumab is potent across diverse RA patient profiles, including those with LJI who typically present with more severe symptoms. The therapy provides early onset of action (within 3 days), sustained control of inflammation, improved physical function, and shield against structural joint impairment.
RMD Open
Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post-hoc analysis of OHZORA and NATSUZORA trials
Ebina K et al.
Comments (0)